Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study
PURPOSE: To evaluate intravitreal aflibercept injections (IAI; also called VEGF Trap-Eye) for
patients with macular edema secondary to central retinal vein occlusion (CRVO). DESIGN …
patients with macular edema secondary to central retinal vein occlusion (CRVO). DESIGN …
Retinal vein occlusions
Retinal vein occlusions (RVOs) have been defined as retinal vascular disorders
characterized by dilatation of retinal veins with retinal and subretinal hemorrhages, macular …
characterized by dilatation of retinal veins with retinal and subretinal hemorrhages, macular …
[HTML][HTML] A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular Edema …
IU Scott, MS Ip, PC VanVeldhuisen… - Archives of …, 2009 - ncbi.nlm.nih.gov
Objective: To compare the efficacy and safety of 1-mg and 4-mg doses of preservative-free
intravitreal triamcinolone with standard care (grid photocoagulation in eyes without dense …
intravitreal triamcinolone with standard care (grid photocoagulation in eyes without dense …
[HTML][HTML] A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema …
MS Ip, IU Scott, PC VanVeldhuisen… - Archives of …, 2009 - ncbi.nlm.nih.gov
Objective: To compare the efficacy and safety of 1-mg and 4-mg doses of preservative-free
intravitreal triamcinolone with observation for eyes with vision loss associated with macular …
intravitreal triamcinolone with observation for eyes with vision loss associated with macular …
Retinal vein occlusions
Retinal vein occlusions (RVOs) have been defined as retinal vascular disorders
characterized by dilatation of the retinal veins with retinal and subretinal hemorrhages and …
characterized by dilatation of the retinal veins with retinal and subretinal hemorrhages and …
Ophthalmic drug delivery systems for the treatment of retinal diseases: basic research to clinical applications
HF Edelhauser, CL Rowe-Rendleman… - … & visual science, 2010 - iovs.arvojournals.org
The ARVO 2009 Summer Eye Research Conference (SERC 2009) on Ophthalmic Drug
Delivery Systems was held July 31 and August 1, 2009, at the National Institutes of Health …
Delivery Systems was held July 31 and August 1, 2009, at the National Institutes of Health …
Management of retinal vein occlusion–consensus document
G Coscas, A Loewenstein, A Augustin, F Bandello… - …, 2011 - karger.com
Retinal vein occlusion (RVO) can have severe consequences for the people affected by the
disease, including visual loss with costly social repercussions. Currently, there is no …
disease, including visual loss with costly social repercussions. Currently, there is no …
Functional and anatomical results after a single intravitreal Ozurdex injection in retinal vein occlusion: a 6‐month follow‐up–The SOLO study
A Bezatis, G Spital, F Höhn, M Maier… - Acta …, 2013 - Wiley Online Library
Purpose: To evaluate the efficacy of intravitreal dexamethasone implants in eyes with
cystoid macular oedema (CME) secondary to branch retinal vein occlusion (BRVO) or …
cystoid macular oedema (CME) secondary to branch retinal vein occlusion (BRVO) or …
Fundus changes in central retinal vein occlusion
SS Hayreh, MB Zimmerman - Retina, 2015 - journals.lww.com
Purpose: To investigate systematically the retinal and optic disk changes in central retinal
vein occlusion (CRVO) and their natural history. Methods: This study comprised 562 …
vein occlusion (CRVO) and their natural history. Methods: This study comprised 562 …
Relationship between visual acuity and retinal thickness during anti–vascular endothelial growth factor therapy for retinal diseases
Purpose To investigate the relationship between best-corrected visual acuity (BCVA) and
central retinal thickness (CRT) in eyes receiving ranibizumab for 3 common retinal diseases …
central retinal thickness (CRT) in eyes receiving ranibizumab for 3 common retinal diseases …